F.D.A. Clears New Cancer-Fighting Drug From Roche

.

F.D.A. Clears New Cancer-Fighting Drug From Roche

A new drug from the drug company Roche has been given the nod by the US Food and Drug Administration (FDA) to improve the treatment of patients suffering from a kind of cancer of the blood and bone marrow.

Roche is calling the new medicine Gazyva which is meant to fight chronic lymphocytic leukemia along with added treatment with chemotherapy. It is meant for those patients who have never before been treated for the same.

Gazyva provides relief in this cancer by destroying cancer cells and enabling the natural immune system of the body to fight against them.

The FDA gave its approval to Gazyva after proof that the drug along with chemotherapy was a better treatment to chemotherapy alone in slowing the progress of the cancer cells.

It was also seen that cancer patients who got treatment from Gazyva combined with chemotherapy had a higher survival rate with 23 months before death, relapse or spreading of the cancer cells.

Earlier treatments treated only with chemotherapy only got 11.1 months.

The new drug Gazyva will be sold by Roche s Genentech unit.


Latest News

Lumber Liquidators Holdings Inc. say Their Products are Safe for Use, Stocks of
Online Pollution Documentary Gets Huge Audience in China in Just Two Days
Patrick Harker Named as Plosser’s successor by the Philadelphia Fed
Official manufacturing Index of China Moves Up
Walmart Wage Hike to Create a Ripple in the Other Industries
NXP Semiconductors to buy Smaller Peer Freescale Semiconductor
Minimum Wage for Tipped Workers Raised in New York
Office Depot and Home Depot Reports Better Than Expected Earnings Results
Attorney General Eric Schneiderman investigating the Selection Process of Casino
Barack Obama Calls for Stricter Standards for Brokers Advising on Saving Plans
Chefs of SoDel Concepts Restaurants Turn Girl Scout Cookies into Innovative Dess
Valeant Pharmaceuticals International Inc. to Acquire Salix Pharmaceuticals Ltd